Academia

Patients who took the weekly glucagon-like peptide 1 (GLP-1) receptor agonist were 21% less likely to experience major kidney disease events and 29% less likely to die due to cardiovascular causes.

Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study.

Stephanie T. Page, MD, PhD, UW Medicine Diabetes Institute, presented on ongoing research and growing interest in new male contraceptive options, such as an oral pill and a hormonal transdermal gel, at the American Urological Association 2024 Annual Meeting.

Survey results from more than 1500 patients with diabetes revealed that 57% believed glucagon-like peptide-1 (GLP-1) weight loss drugs alone could be a "silver bullet" for managing their health goals.

The novel intravesical drug delivery system releases erdafitinib locally within the bladder while limiting systemic toxicities.

Updated findings from SunRISe-1 also showed that all but 1 responder achieved complete response within 12 weeks of treatment with the targeted gemcitabine delivery system.

Speakers discussed the disparities in prostate-specific antigen (PSA) screening rates among different racial groups and explored the potential of free PSA percentage as a predictive marker for future prostate cancer risk.

A predictive model using plasma proteins as biomarkers predicted hepatocellular carcinoma development more accurately than a model based on traditional lifestyle risk factors in a recent study.

Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.

"Off the shelf" CAR T-cell therapies could offer a solution in chronic lymphocytic leukemia, where T-cell exhaustion creates treatment challenges.

While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).

Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.

A tumor board looked to studies in ovarian cancer for guidance on use of immunotherapy in a rare case of clear cell carcinoma of the cervix.

Patients who responded positively to shunt treatment experienced more beneficial changes in their heart's structure and function compared with nonresponders.

A single injection of a gene therapy was well tolerated and showed the potential to control exudation in patients with neovascular age-related macular degeneration (wet AMD).

The authors say a standard method of assessing metabolic tumor volume would be needed for its use to become widespread.

An alternative dose of ipilimumab and nivolumab had less toxicity than a conventional dose, the results show.

For most patients younger than age 60 with polycythemia vera (PV) who are not considered high risk, cytoreductive therapies are withheld despite being highly effective.

Treatment resistance remains a major challenge in the treatment of acute myeloid leukemia (AML), and leveraging actionable therapeutic targets is far from straightforward.

A recent study found that certain gene variants may be prognostic for residual disease following resection in patients with ovarian cancer.

Following these positive 36-week results, Silence Therapeutics plans to announce 48-week results of the ongoing ALPACAR-360 study in Q2 of 2024.

A recent study found that tumor-stroma proportion was a reliable marker of chemoresistance, progression-free survival, and overall survival in high-grade serous ovarian cancer.

The analysis revealed that viral hepatocellular carcinoma (HCC) had a distinct microbial signature vs non-viral HCC, although only hepatitis B virus–related HCC showed a significantly diverse tumor microbiome.

Patients with early-stage hepatocellular carcinoma (HCC) and those with advanced-stage disease exhibited distinct gut microbiota diversity and alterations, with future studies warranted to investigate the mechanisms underlying the interactions between gut microbiota and HCC progression.

A recent review suggests patients diagnosed with ovarian cancer may benefit from nutritional intervention as part of disease management, but research on the topic has been limited and further investigation is warranted.

In patients with high-grade ovarian cancer, an increased proportion of CD3+ CD137+ tumor infiltrating lymphocytes (TILs) correlated with favorable overall survival outcomes. However, proportions of CD3+ or CD3+ CD8+ TILs did not show significant associations with OS.

A predictive model utilizing serum metabolic profiles was able to distinguish ovarian cancer from control samples with 93% accuracy, according to a new study.

In a cohort with more than half a million women with endometrial, ovarian, or cervical cancer, less than 1% were enrolled in a clinical trial, and more than 85% of enrolled women were White.